1. Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis
- Author
-
Jia Che, Lanlan Huang, Huanliang Liu, Zhiting Liu, Xiangling Yang, Chuangyu Wen, Aihua Lin, and Lun Pan
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,colorectal cancer ,Cochrane Library ,Biology ,chemotherapy ,thymidine phosphorylase ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,5-fluorouracil ,Thymidine phosphorylase ,Chemotherapy ,Hazard ratio ,Cancer ,Articles ,medicine.disease ,meta-analysis ,030104 developmental biology ,Fluorouracil ,030220 oncology & carcinogenesis ,Meta-analysis ,medicine.drug - Abstract
In the past decades, various studies have suggested a possible link between thymidine phosphorylase (TP) level and colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy; however, they have arrived at inconsistent results. Therefore, the present meta-analysis aimed to disclose a more comprehensive evaluation of this relationship. PubMed, the Cochrane Library, Ovid MEDLINE, Embase and China National Knowledge Infrastructure were systematically searched for studies that evaluated the prognostic value of TP in CRC. Stata 12.0 software was used to test the heterogeneity and evaluate the overall test performance. A total of 15 studies, including 1,225 patients, were included. The summary estimates of TP for CRC treated with 5-FU-based chemotherapy indicated a moderately positive prognosis with a hazard ratio (HR) of 0.76 (P=0.031) for overall survival and a HR of 0.711 (P=0.022) for relapse-free survival. On the basis of the present meta-analysis, TP could be promising and meaningful in the prognosis of CRC treated with 5-FU-based chemotherapy.
- Published
- 2017